Eldon C. Mayer III, M.B.A.
Net Worth

Last updated:

What is Eldon C. Mayer III, M.B.A. net worth?

The estimated net worth of Mr. Eldon C. Mayer III, M.B.A. is at least $15,909,766 as of 17 Mar 2023. He owns shares worth $96,726 as insider, has earned $41,440 from insider trading and has received compensation worth at least $15,771,600 in Eiger BioPharmaceuticals, Inc..

What is the salary of Eldon C. Mayer III, M.B.A.?

Mr. Eldon C. Mayer III, M.B.A. salary is $657,150 per year as Executive Vice President & Chief Commercial Officer in Eiger BioPharmaceuticals, Inc..

How old is Eldon C. Mayer III, M.B.A.?

Mr. Eldon C. Mayer III, M.B.A. is 64 years old, born in 1961.

What stocks does Eldon C. Mayer III, M.B.A. currently own?

As insider, Mr. Eldon C. Mayer III, M.B.A. owns shares in one company:

Company Title Shares Price per share Total value
Eiger BioPharmaceuticals, Inc. (EIGR) Executive Vice President & Chief Commercial Officer 56,073 $1.73 $96,726

What does Eiger BioPharmaceuticals, Inc. do?

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

EIGR logo
EIGR
Eiger BioPharmaceuticals, Inc.
$1.73

Eldon C. Mayer III, M.B.A. insider trading

Eiger BioPharmaceuticals, Inc.

Mr. Eldon C. Mayer III, M.B.A. has made 5 insider trades between 2001-2023, according to the Form 4 filled with the SEC. Most recently he sold 2,520 units of EIGR stock worth $2,696 on 17 Mar 2023.

The largest trade he's ever made was exercising 7,500 units of EIGR stock on 26 Nov 2018. As of 17 Mar 2023 he still owns at least 56,073 units of EIGR stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 2,520 $1.07 $2,696
Sale
Common Stock 1,875 $1.07 $2,008
Sale
Common Stock 1,657 $5.6 $9,274
Sale
Common Stock 1,560 $4.95 $7,722
Sale
Common Stock 1,690 $11.68 $19,739
Purchase
Common Stock 5,000 $13.52 $67,605
Purchase
Common Stock 4,000 N/A N/A
Purchase
Common Stock 7,500 N/A N/A
Purchase
Common Stock 7,500 N/A N/A
Purchase
Common Stock 6,000 N/A N/A

Eiger BioPharmaceuticals key executives

Eiger BioPharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Dr. Evan Loh (66) Chief Executive Officer of Paratek Pharmaceuticals & Director
  • Dr. Jeffrey S. Glenn (62) Founder, Scientific Advisor & Independent Director
  • Mr. David A. Cory M.B.A., R.Ph., R.Ph, MBA (61) Bus. Founder, Pres, Chief Executive Officer & Director
  • Mr. Eldon C. Mayer III, M.B.A. (64) Executive Vice President & Chief Commercial Officer
  • Mr. Sriram Ryali M.B.A. (44) Chief Financial Officer